NeoMatrix, Novation sign new technology agreement

Feb 2 2010

NeoMatrix, Inc., developers of the innovative HALO® Breast Pap Test, has been awarded a new technology agreement by Novation, the supply contracting company of VHA Inc, University HealthSystem Consortium (UHC) and Provista.  This agreement includes the HALO® Console, HALO® Cart, HALO® Patient Interface Cassette and HALO® Specimen Collection Cups.

The agreements between NeoMatrix and Novation are effective February 1, 2010 – January 31, 2013.  The contracts will have an initial three-year term with two one-year extension options, with firm pricing for the initial term.

"We are quite proud of being awarded this new technology agreement and look forward to a long-term, mutually beneficial partnership with Novation," said John Stroh, Chief Executive Officer and Director of NeoMatrix.  "We consider this contract to be a sign of the dedication of NeoMatrix, Inc., to improving the breast health of women across the country."

Based on the same science as the PAP test for cervical cell changes, HALO® is the only FDA-cleared risk assessment tool for non-hereditary breast cancer.  HALO can help identify women at increased risk for breast cancer years before a lump might appear, allowing for clinical intervention aimed at prevention and early detection.